- Home
- FBRX vs OCCI Comparison
FBRX vs OCCI Comparison
Compare FBRX & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- OCCI
- Stock Information
- Founded
- FBRX N/A
- OCCI N/A
- Country
- FBRX United States
- OCCI United States
- Employees
- FBRX N/A
- OCCI N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- FBRX Health Care
- OCCI Finance
- Exchange
- FBRX Nasdaq
- OCCI Nasdaq
- Market Cap
- FBRX 154.5M
- OCCI 160.5M
- IPO Year
- FBRX N/A
- OCCI N/A
- Fundamental
- Price
- FBRX $11.60
- OCCI $6.02
- Analyst Decision
- FBRX Strong Buy
- OCCI
- Analyst Count
- FBRX 2
- OCCI 0
- Target Price
- FBRX $61.00
- OCCI N/A
- AVG Volume (30 Days)
- FBRX 73.6K
- OCCI 115.8K
- Earning Date
- FBRX 08-13-2025
- OCCI 12-11-2023
- Dividend Yield
- FBRX N/A
- OCCI 24.32%
- EPS Growth
- FBRX N/A
- OCCI N/A
- EPS
- FBRX N/A
- OCCI N/A
- Revenue
- FBRX N/A
- OCCI N/A
- Revenue This Year
- FBRX N/A
- OCCI N/A
- Revenue Next Year
- FBRX N/A
- OCCI $10.19
- P/E Ratio
- FBRX N/A
- OCCI N/A
- Revenue Growth
- FBRX N/A
- OCCI N/A
- 52 Week Low
- FBRX $4.11
- OCCI $5.47
- 52 Week High
- FBRX $28.68
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- FBRX 53.91
- OCCI 41.88
- Support Level
- FBRX $10.02
- OCCI $5.77
- Resistance Level
- FBRX $10.99
- OCCI $6.12
- Average True Range (ATR)
- FBRX 0.86
- OCCI 0.09
- MACD
- FBRX -0.06
- OCCI -0.03
- Stochastic Oscillator
- FBRX 60.78
- OCCI 47.17
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation primarily through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.